NEW YORK (GenomeWeb News) – Molecular diagnostics firm OpGen has raised a total of $20 million in its Series B financing round, to be used to advance commercialization of its platform for the generation of de novo whole genome restriction maps.
In a document filed with the US Securities and Exchange Commission this week, the Gaithersburg, Md.-based firm disclosed it had raised $11.9 million. According to a company spokesman, the funds raised include part of a $17 million Series B round announced in September and an additional $3 million, making the total raised in the B round $20 million.
The $17 million raised in September was led by jVen Capital and included participation from existing investors CHL Medical Partners, Highland Capital Partners, Mason Wells Biomedical, and Versant Ventures. The additional $3 million came from new investors, whom OpGen declined to identify.
The funds will be used for the continued commercialization of OpGen's Argus Optical Mapping System, which uses optical mapping technology for whole-genome sequence assembly and finishing. The system was launched in the spring.